Quanterix announces kit for Alzheimer's disease detection

By LabPulse.com staff writers

June 2, 2020 -- Biomarker analysis firm Quanterix has announced the Simoa P-Tau181 V2 kit to help detect Alzheimer's disease.

The test is designed to detect tau phosphorylated at threonine 181 (p-tau181), a biomarker for Alzheimer's disease found in cerebral spinal fluid, serum, and plasma. The company is positioning the test as a blood-based screening method to help identify patients with Alzheimer's disease prior to showing clinical symptoms. In addition to enabling earlier diagnosis, the test could also help differentiate Alzheimer's disease from other neurodegenerative disorders, according to the company.

The test is part of Quanterix's Simoa kits, which use singleplex and multiplex testing to identify key disease biomarkers. Quanterix will share more research findings and discuss how clinicians can gain early access to the assay during a webinar on June 3 at 10 a.m. EDT.

Blood biomarkers signal concussion in college athletes
Changes to biomarkers in blood tests matched concussion injuries in a recent study of college athletes. The results suggest potential for blood testing...
Quanterix to make $75M public offering
Biomarker analysis firm Quanterix said it plans to make a public offering of $75 million shares of its common stock.
Quanterix boosts NfL assays with UmanDiagnostics acquisition
Quanterix is building its testing offerings for neurofilament light (NfL) -- an increasingly important biomarker in Alzheimer's disease and other neurological...
Cerebrospinal fluid test helps pinpoint dementia disorders
Testing for neurofilament light protein in cerebrospinal fluid appears to be helpful for differentiating some neurological conditions, such as frontotemporal...

Copyright © 2020 LabPulse.com

Last Updated ls 6/2/2020 12:24:27 PM